Alexion Pharmaceuticals (ALXN) PT Lowered to $151 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 30 | New: 16
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 30 | New: 16
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $151.00 (from $156.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Raymond James Downgrades First Busey (BUSE) to Market Perform
- Boeing (BA) PT Lowered to $240 at Freedom Broker
- Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
